



Liberia COVID-19 Emergency Response Project (P173812)

WESTERN AND CENTRAL AFRICA | Liberia | Health, Nutrition & Population Global Practice |
IBRD/IDA | Investment Project Financing | FY 2020 | Seq No: 5 | ARCHIVED on 23-Dec-2022 | ISR54012 |

Implementing Agencies: Ministry of Health, Republic of Liberia

Key Dates

Key Project Dates

Bank Approval Date: 09-Apr-2020

Effectiveness Date: 13-Apr-2020

Planned Mid Term Review Date: 30-Sep-2022

Actual Mid-Term Review Date: 24-Jun-2022

Original Closing Date: 30-Apr-2022

Revised Closing Date: 30-Sep-2024

Project Development Objectives

Project Development Objective (from Project Appraisal Document)

The development objective is to prepare and respond to the COVID-19 pandemic in Liberia

Has the Project Development Objective been changed since Board Approval of the Project Objective?

No

Components Table

Name

Component 1: Emergency Preparedness Response:(Cost \$20.75 M)

Component 2: Program Management and Coordination, Monitoring and Evaluation:(Cost \$3.12 M)

Unallocated:(Cost \$0.63 M)

Overall Ratings

Name	Previous Rating	Current Rating
Progress towards achievement of PDO	<input type="checkbox"/> Moderately Satisfactory	<input type="checkbox"/> Satisfactory
Overall Implementation Progress (IP)	<input type="checkbox"/> Moderately Satisfactory	<input type="checkbox"/> Satisfactory
Overall Risk Rating	<input type="checkbox"/> Substantial	<input type="checkbox"/> Substantial

Implementation Status and Key Decisions

Over the past year, there has been significant progress in the implementation of planned activities. With support from the project and other development partners, the country has fully vaccinated 77% of the target population (12 years and older) and 69% of the total population, as of October 31, 2022. This makes Liberia one of the leading countries in COVID-19 vaccination coverage in Africa. These successes can be attributed to concerted efforts by the Ministry of Health (MoH) and the National Public Health Institute of Liberia (NPHIL) during the past year, in which the country has seen a steep increase in COVID-19 vaccination coverage and a deep decline in new confirmed cases and deaths. Funds from the project are being used to strengthen the broader vaccination system through the procurement of equipment for the transportation and storage of vaccines. Furthermore, the country has continued to strengthen surveillance and detection capacities through the (i) training of healthcare providers; (ii) equipping of laboratories and training of laboratory personnel; (iii) community-based sensitization and risk communication; and (iv) equipping of isolation and treatment centers. These measures have contributed to achieving near-zero transmission rates, and reduced hospitalization and mortality due to COVID-19. Overall, the project is on track to achieving its development objective.



MPA Program Development Objective

The Program Development Objective is to prevent, detect and respond to the threat posed by COVID-19 and strengthen national systems for public health preparedness

Multiphase Programmatic Approach (MPA) Status

Sustained efforts continue to be made to advance the implementation of the 87 MPA operations. As of November 15, 2022, 88 MPA-projects had been approved with a total commitment of US\$4.3 billion. One operation (Guatemala) was cancelled in mid-September 2021, at the request of the Government. Six parent projects were restructured to include vaccine-related procurement. **Total disbursements as of November 15, 2022, amount to US\$3.74 billion or 87% of overall commitments.** This amount does not include disbursements under MPA-V operations which are reported together with AF-V operations. **Loans and Credits denominated in SDRs and Euros are being affected because of fluctuations between the SDRs and Euros against the US dollar.** To ensure that commitments are not made beyond available funds, teams task-managing these operations are carefully monitoring payments as projects reach the end of their implementation period. At this late stage of implementation, several operations are processing refunds to the special accounts and therefore, total disbursements are affected. **Four country operations closed by the end of FY22. Some operations are processing extension of closing dates. At present, however, nine operations are scheduled to close by the end of the CY.**

Sixty-seven (67) country projects or 77% of projects approved have reached 70-100% disbursement (reasons for >100% disbursements relate to fluctuations between the Euro and the SDR against the US\$). **Out of the 67 operations, 51 operations or 76% have disbursed over 90+% of commitments.** Out of the 67 operations, **33 operations or 49% are fully disbursed.** There are 12 operations with disbursements under 50%, which is worrisome. Out of these 12 operations, one has not disbursed (AFW), and two have disbursed 30 percent or less. The projects are benefitting around 3.7 billion people or 50% of the global population. If countries that have AF-V operations are counted, the projects are benefitting 4.1 billion of 51 percent of total world population. Of the 87 active projects: (i) 33 are in Africa – 12 in AFE and 21 in AFW; (ii) 12 in East Asia; (iii) 14 in Europe and Central Asia; (iv) 11 in Latin America and the Caribbean; (v) 8 in Middle East and North Africa; and (vi) 9 in South Asia. Eighty-six (86) or 99% of projects approved are disbursing. MNA has the highest percentage of disbursements, followed by SRA, EAP, ECA, LAC, AFW, and AFE. Retroactive Financing continues to represent 26% of commitments. Country teams for operations, which have been under implementation for twelve months or more or have disbursed 50% or more of commitments by June 30, 2022, have prepared Mid-Term Review (MTR) ISRs and other documentation to inform the Global MPA MTR, which is being prepared by the EOC this FY.

Streamlined procedures, delegated approvals, coupled with flexible project design and intensified efforts across the Bank have contributed to the progress. Implementation is being guided by Bank teams working in parallel with other health related projects, including Additional Financing operations supporting vaccine procurement and deployment efforts. Notwithstanding challenges of implementation, the MPA is on track to achieve its PrDO, which is to prevent, detect and respond to the threat posed by COVID-19 and strengthen national systems for public health preparedness. It is clear that the flexibility of project design has played an important role in achieving the PrDO as many projects have taken advantage of this to restructure operations to allow, *inter alia*, reallocation of funds among components and activities according to the country's evolving needs. The high level of disbursements attests to the strong implementation of the Bank' response thanks to the commitment of counterparts supported by Bank country teams.



The Additional Financing (MPA AF-V) to the COVID-19 Strategic Preparedness and Response Program utilizing the Multiphase Programmatic Approach (Global COVID-19 MPA) was approved by the Board on October 13, 2021. The AF-V was approved with an envelope of US\$12 billion (\$6 billion from IDA and \$6 billion from IBRD) in financing. **On June 30, 2021, President Malpass announced the expansion of financing available for COVID-19 vaccine financing to \$20 billion over the next 18 months, adding \$8 billion to the previously announced \$12 billion.** This financing is critical to expand affordable and equitable financing for vaccine purchase and deployment. The AF-V is expected to enable vaccination for up to 750 million people, with potential surge capacity for an additional 250 million people in the poorest countries while scaling support to strengthen immunization delivery, with design flexibility at the country level. The AF-V is a scale-up of planned vaccination activities anticipated and supported under the Global COVID-19 MPA and a key contribution to the WBG's overall COVID-19 response. **As of October 7, 2022, 630.5 million doses had been procured with Bank financing out of which 467.1 million doses have been delivered and 414.3 doses had been administered or 65.7 percent of those procured.**

As of November 15, 2022, the Bank has approved 116 operations (including MPA-V operations) to support vaccine procurement and rollout in 80 countries amounting to \$10.1 billion. The 116 operations approved, include 6 operations that involved restructuring of parent projects (Bhutan, Cameroon, North Macedonia, Philippines, and Pakistan) and in the case of Lebanon, restructuring of the Health Resilience Project. Of the 116 approved operations: (i) 64 are in Africa – 29 in AFE and 35 in AFW; (ii) 10 in East Asia and the Pacific; (iii) 11 in Europe and Central Asia; (iv) 13 in Latin America and the Caribbean; (v) 9 in Middle East and North Africa; and (vi) 9 in South Asia. Thirty-five (35) operations have been approved so far this Calendar Year; two other operations are being processed for approval later in the calendar year. Seventy-two (72) projects or 62 percent of total operations approved are disbursing. IDA continues to represent 44 percent and IBRD 56 percent of disbursements. **Total disbursements as of November 15, 2022, under these projects amount to US\$4.93 billion or 49% of overall commitments.** Disbursements under MPA-V operations are included in this total while disbursements under the six restructured projects are counted under parent projects. **Twenty-eight (28) or 24% AF-V and MPA-V operations have disbursed 70% or more of their commitments. Out of the 28, twelve operations or 43% have disbursed 90%.** Retroactive Financing (RF) represents 45% of overall commitments. High RF has been authorized under different operations - Indonesia and Ukraine (100%), Panama and Turkey (90%), Argentina and Guyana (80%), and Belize, Iraq and Sri Lanka (70%). One hundred and eight (108) loan/financing agreements or 93 percent of project approved have been signed. Ninety-nine (99) loan/financing agreements or 85 percent of projects approved have become effective. As with the MPA operations, streamlined procedures, delegated approval, coupled with flexible project design, and intensified efforts across the Bank have contributed to the rapid design, processing, and implementation of the operations.

Risks

Systematic Operations Risk-rating Tool

Risk Category	Rating at Approval	Previous Rating	Current Rating
Political and Governance	☐ Substantial	☐ Substantial	☐ Substantial
Macroeconomic	☐ Substantial	☐ Substantial	☐ Substantial
Sector Strategies and Policies	☐ Moderate	☐ Substantial	☐ Substantial
Technical Design of Project or Program	☐ Low	☐ Moderate	☐ Moderate
Institutional Capacity for Implementation and Sustainability	☐ Substantial	☐ Substantial	☐ Substantial



Fiduciary	<input type="checkbox"/> Substantial	<input type="checkbox"/> Substantial	<input type="checkbox"/> Substantial
Environment and Social	<input type="checkbox"/> Substantial	<input type="checkbox"/> Substantial	<input type="checkbox"/> Substantial
Stakeholders	<input type="checkbox"/> Low	<input type="checkbox"/> Moderate	<input type="checkbox"/> Moderate
Other	--	--	<input type="checkbox"/> Substantial
Overall	<input type="checkbox"/> Substantial	<input type="checkbox"/> Substantial	<input type="checkbox"/> Substantial

Results

PDO Indicators by Objectives / Outcomes

The development objective is to prepare and respond to the COVID-19 pandemic in Liberia				
▶ Country has activated its Public Health Emergency Operations Center or a coordination mechanism for COVID-19 (Yes/No, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	No	Yes	Yes	Yes
Date	30-Jun-2022	31-Mar-2022	28-Oct-2022	30-Sep-2024
Comments:	Indicator respond to country country readiness for coordinating the COVID-19 response			
▶ Suspected cases of COVID-19 reported and investigated based on national guidelines, segregated by gender (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	3.00	5,578.00	7,999.00	8,000.00
Date	31-Mar-2020	31-Mar-2022	28-Oct-2022	30-Sep-2024
Comments:	Cases of suspected COVID cases reported and investigated			
◻ Suspected cases of COVID-19 in women reported and investigated based on national guidelines (Number, Custom Supplement)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	2,580.00	3,923.00	3,000.00
▶ Designated laboratories with COVID-19 diagnostic equipment, test kits, and reagents (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	1.00	3.00	3.00	3.00
Date	31-Mar-2020	31-Mar-2022	28-Oct-2022	30-Sep-2024
Comments:	Designated laboratories with COVID-19 diagnostic equipment, test kits, and reagents			



► Acute health care facilities with isolation capacities (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	2.00	6.00	6.00	6.00
Date	31-Mar-2020	31-Mar-2022	28-Oct-2022	30-Sep-2024
Comments:	Acute health care facilities with isolation capacities			
► Counties with pandemic preparedness and response plans per MOH guidelines (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	80.00	100.00	100.00
Date	31-Mar-2020	31-Mar-2022	28-Oct-2022	30-Sep-2024
► Facilities with healthcare workers trained in COVID-19 emergency preparedness and other emergency response (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	60.00	100.00	80.00
Date	31-Mar-2020	31-Mar-2022	28-Oct-2022	30-Sep-2024
<input type="checkbox"/> Facilities with female healthcare workers trained in COVID-19 emergency preparedness and other emergency response (Percentage, Custom Supplement)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	60.00	60.00	80.00
► Country has developed and operationalized a referral system to care for COVID-19 patients (Yes/No, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	No	Yes	Yes	Yes
Date	31-Mar-2020	31-Mar-2022	28-Oct-2022	30-Sep-2024
► Population completely vaccinated against COVID-19 (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	1.00	13.40	69.00	65.60
Date	01-Jun-2021	31-Mar-2022	28-Oct-2022	30-Sep-2024
<input type="checkbox"/> Population completely vaccinated who are women (Percentage, Custom Supplement)				
	Baseline	Actual (Previous)	Actual (Current)	End Target



Value	40.00	46.00	49.00	50.00
<input type="checkbox"/> Population between 12 to 17 years of age completely vaccinated (Percentage, Custom Supplement)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	12.90	13.27
<input type="checkbox"/> Population over 60 years completely vaccinated (Percentage, Custom Supplement)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	54.00	4.92
<input checked="" type="checkbox"/> Population that have received at least one booster shot in addition to the complete initial protocol (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.04	0.30	15.00
Date	01-Jan-2022	31-Mar-2022	28-Oct-2022	30-Sep-2024
<input type="checkbox"/> Female population that have received at least one booster shot in addition to the complete initial protocol (Percentage) (Percentage, Custom Supplement)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	0.00	50.00
<input checked="" type="checkbox"/> Counties with at least two facilities providing COVID-19 vaccination services (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	50.00	100.00	100.00
Date	15-Jun-2021	31-Mar-2022	28-Oct-2022	30-Sep-2024

Intermediate Results Indicators by Components

Component 1: Emergency Preparedness Response				
<input checked="" type="checkbox"/> Counties that have activated EOC inline with the national EOC activation as part of COVID-19 response (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	100.00	100.00	80.00
Date	31-Mar-2020	31-Mar-2022	28-Oct-2022	30-Sep-2024



► At least one multi-sectoral simulation exercise conducted with results incorporated into national COVID-19 preparedness and response plans (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	1.00	2.00	2.00	3.00
Date	31-Mar-2020	31-Mar-2022	28-Oct-2022	30-Sep-2024
► Counties with EOCs functioning according to standard operating procedures (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	100.00	100.00	80.00
Date	31-Mar-2020	31-Mar-2022	28-Oct-2022	30-Sep-2024
► COVID-19 vaccine doses procured (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	381,600.00	381,600.00	300,000.00
Date	01-Jun-2021	31-Mar-2022	28-Oct-2022	30-Sep-2024
► National, subnational, facility-based and mobile staff trained in COVID-19 vaccine cold chain storage and handling (by gender) (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	375.00	1,353.00	1,000.00
Date	01-Jun-2021	31-Mar-2022	28-Oct-2022	30-Sep-2024
□ National, subnational, facility-based and mobile female staff trained in COVID-19 vaccine cold chain storage and handling (Number, Custom Supplement)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	135.00	406.00	400.00
► Facilities equipped (installation complete) with energy-efficient storage facilities for storing specimens and temperature sensitive medical supplies (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	72.00	50.00
Date	01-Jun-2021	31-Mar-2022	28-Oct-2022	30-Sep-2024
► Pharmacovigilance system adapted to detect AEFI following administration of the COVID-19 vaccine (Yes/No, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target



Value	No	Yes	Yes	Yes
Date	01-Jun-2021	31-Mar-2022	28-Oct-2022	30-Sep-2024
▶ AEFIs reported via the electronic notification system (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	15.00	100.00	100.00
Date	01-Jun-2021	31-Mar-2022	28-Oct-2022	30-Sep-2024
▶ Community engagement plan developed to increase the population's demand for the COVID-19 vaccine (Yes/No, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	No	Yes	Yes	Yes
Date	01-Jun-2021	31-Mar-2022	28-Oct-2022	30-Sep-2024
▶ Counties where radio stations broadcast awareness campaigns on COVID-19 and the COVID-19 vaccination campaign (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	5.00	15.00	15.00
Date	01-Jun-2021	31-Mar-2022	28-Oct-2022	30-Sep-2024
▶ Vaccinators trained on SEA/SH (by gender) (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	0.00	1,000.00
Date	01-Jun-2021	31-Mar-2022	28-Oct-2022	30-Sep-2024
☐ Female vaccinators trained on SEA/SH (Number, Custom Supplement)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	0.00	300.00
▶ Health centers reporting no stock-out of tracer IPC materials on the first day of each month (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	30.00	43.00	50.00
Date	31-Mar-2020	31-Mar-2022	28-Oct-2022	30-Sep-2024



► Laboratories established/upgraded to support diagnosis of COVID-19 and other major infectious diseases (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	1.00	3.00	3.00	3.00
Date	31-Mar-2020	31-Mar-2022	28-Oct-2022	30-Sep-2024

► Laboratory staff trained to conduct COVID-19 diagnosis (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	2.00	20.00	20.00	10.00
Date	31-Mar-2020	31-Mar-2022	28-Oct-2022	30-Sep-2024

Component 2: Project Management and Coordination, Monitoring & Evaluation

► Point of entry that report having received a supervisory visit during the preceding month (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	80.00	80.00	80.00
Date	31-Mar-2020	31-Mar-2022	28-Oct-2022	30-Sep-2024

► Prioritized facilities reporting supervisory visits on the first day of each month (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	5.00	6.00	5.00
Date	31-Mar-2020	31-Mar-2022	28-Oct-2022	30-Sep-2024

► EOC organized as part of COVID-19 response (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	20.00	20.00	20.00
Date	31-Mar-2020	31-Mar-2022	28-Oct-2022	30-Sep-2024

► Refurbished/upgraded health facilities implementing customer satisfaction survey (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	0.00	5.00
Date	14-Apr-2020	31-Mar-2022	28-Oct-2022	30-Sep-2024



► Counties with budgeted micro-plans for COVID-19 vaccination campaign (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	8.00	15.00	15.00
Date	01-Jun-2021	31-Mar-2022	28-Oct-2022	30-Sep-2024
► Training of Project Implementation Unit (PIU) staff (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	2.00	15.00	10.00
Date	01-Jun-2021	31-Mar-2022	28-Oct-2022	30-Sep-2024
► Grievances addressed within the stipulated timeframe (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	0.00	100.00
Date	30-Jun-2021	31-Mar-2022	28-Oct-2022	30-Sep-2024

Performance-Based Conditions

Data on Financial Performance

Disbursements (by loan)

Project	Loan/Credit/TF	Status	Currency	Original	Revised	Cancelled	Disbursed	Undisbursed	% Disbursed
P173812	IDA-66090	Effective	USD	3.75	3.75	0.00	3.20	0.55	85%
P173812	IDA-71990	Not Effective	USD	2.80	2.80	0.00	0.00	2.77	0%
P173812	IDA-D6080	Effective	USD	3.75	3.75	0.00	3.20	0.61	84%
P173812	IDA-D9000	Effective	USD	7.00	7.00	0.00	5.09	1.54	77%
P173812	IDA-E1140	Not Effective	USD	6.20	6.20	0.00	0.00	6.06	0%
P173812	TF-B6141	Effective	USD	1.00	1.00	0.00	0.00	1.00	0%


Key Dates (by loan)

Project	Loan/Credit/TF	Status	Approval Date	Signing Date	Effectiveness Date	Orig. Closing Date	Rev. Closing Date
---------	----------------	--------	---------------	--------------	--------------------	--------------------	-------------------



P173812	IDA-66090	Effective	09-Apr-2020	10-Apr-2020	13-Apr-2020	30-Apr-2022	30-Sep-2024
P173812	IDA-71990	Not Effective	30-Jun-2022	04-Jul-2022	--	30-Sep-2024	30-Sep-2024
P173812	IDA-D6080	Effective	09-Apr-2020	10-Apr-2020	13-Apr-2020	30-Apr-2022	30-Sep-2024
P173812	IDA-D9000	Effective	30-Jun-2021	06-Jul-2021	03-Aug-2021	30-Sep-2024	30-Sep-2024
P173812	IDA-E1140	Not Effective	30-Jun-2022	04-Jul-2022	--	30-Sep-2024	30-Sep-2024
P173812	TF-B6141	Effective	30-Jun-2021	06-Jul-2021	03-Aug-2021	30-Sep-2022	30-Sep-2023

Cumulative Disbursements



Restructuring History

Level 2 Approved on 23-Sep-2022

Related Project(s)

P176336-Additional Financing on Vaccines for the Liberia COVID-19 Emergency Response Project ,P178479-Liberia COVID-19 Emergency Preparedness and Response Project Second Additional Financing